Overview

EVP-6124 Hepatic Impairment Study

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics of EVP-6124 and metabolites after a single oral dose in subjects with mild, moderate and severe hepatic impairment compared with subjects with normal hepatic function.

Phase:

Phase 1

Details

Lead Sponsor:

FORUM Pharmaceuticals Inc

Collaborator:

PRA Health Sciences